Product Description
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12076183/)
Mechanisms of Action: AT1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Cosette Pharmaceuticals
Company Location:
Company Founding Year: None
Additional Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic: Australia, Brazil, China
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hypertension
Phase 2: COVID-19|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12620001249943p |
HTA5347 | P2 |
Not yet recruiting |
COVID-19 |
2021-04-01 |
|||
ACTRN12618000982213p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Kidney Diseases |
2019-01-28 |
46% |
||
NCT06608472 |
ATHESA | P3 |
Not yet recruiting |
Hypertension |
2028-04-30 |
17% |
2024-11-16 |
Patient Enrollment|Primary Endpoints|Treatments |
CTR20260224 |
CTR20260224 | P1 |
Completed |
Hypertension |
2025-08-25 |
2026-01-28 |
Treatments |
|
CTR20241045 |
CTR20241045 | P3 |
Completed |
Hypertension |
2025-08-26 |
2026-03-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20231189 |
CTR20231189 | P1 |
Completed |
Hypertension |
2023-07-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20231188 |
CTR20231188 | P1 |
Completed |
Hypertension |
2023-07-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/11/2025 |
News Article |
Termination of Proposed Acquisition of Mayne Pharma |
|
11/19/2025 |
News Article |
Ituran to Ring the Nasdaq Opening Bell in Celebration of Its 30th Anniversary and 20 Years as a Nasdaq-Listed Company |
|
10/29/2025 |
News Article |
ROCK & ROLL HALL OF FAME ANNOUNCES ADDITIONAL PRESENTERS AND PERFORMERS FOR 2025 INDUCTION CEREMONY |
|
02/20/2025 |
News Article |
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women's Health and Dermatology |